Dividends & Buybacks ·
Bone Biologics shareholders approve reverse split up to 1-for-10 and elect four directors
BBLGBone Biologics Corp
Bone Biologics Corporation held its Annual Meeting of Stockholders on September 28, 2026. Shareholders approved an amendment to the Certificate of Incorporation authorizing the Board to effect a reverse stock split within a range of 1-for-2 to 1-for-10 at its discretion. The company also elected four directors: Bruce Stroever, Siddhesh Angle, Robert Gagnon, and Philip Meikle. Additionally, shareholders ratified executive compensation, approved the appointment of Weinberg & Company as independent auditor, and authorized potential warrant-related share issuances exceeding 20% of outstanding stock to comply with Nasdaq rules. Bone Biologics Corp operates in the biotechnology industry, focusing on developing regenerative medicine therapies.